Clinical Trials Logo

Clinical Trial Summary

Young adults who exhibit "bipolar phenotype" (BPP), defined as occasional episodes of mood elevation and heightened activity, are at risk for several psychiatric disorders, including problem use of drugs and alcohol. Mood elevation has been linked to higher alcohol consumption and alcohol use disorders. Individuals with BPP show elevated lifetime prevalence of alcohol use disorders (between 39%-61%), figures that exceed those reported in both major depression and schizophrenia. Recently, the investigators demonstrated in a controlled laboratory study that individuals with BPP (but not meeting criteria for full Bipolar I Disorder), report dampened responses to a single dose of alcohol, compared to placebo. In the current study, the investigators seek to extend these findings to determine if young adults reporting BPP, based on a questionnaire, will exhibit reduced responses to other rewarding stimuli, such as d-amphetamine and sweet tastes. The investigators hypothesize that the BPP individuals will exhibit dampened subjective responses to stimulant and sweet taste rewards compared to healthy controls.


Clinical Trial Description

This study will extend the understanding of risk factors for drug or alcohol misuse, or other reward-related behaviors. The investigators previously showed that individuals who report occasional feelings of high energy and excitability experience less effect from a single dose of alcohol, compared to people who have not experienced these effects. Now the investigators wish to determine if this dampened response also occurs with other rewards, namely feelings of wellbeing after a dose of amphetamine, or liking of a sweet solution. Individuals who exhibit the BPP (i.e., periods of excitability) also are more likely to develop alcohol problems, substance misuse, and weight gain and obesity. Therefore, the investigators will test the working hypothesis that young adults who report having these experiences, based on a questionnaire measure (i.e., BPP individuals) will show dampened subjective responses to both single oral doses of amphetamine or sweet palatable tastes. The investigators will also obtain objective measures (e.g. Respiratory Sinus Arrhythmia and heart rate) to amphetamine and sweet taste, to establish whether the dampened subjective response extends to physiological indices as well. This study will extend the previous literature regarding the blunted effects of alcohol in BPP individuals and will suggest possible mechanisms that promote broader addictive behaviors in individuals with mood disturbance. Importantly, the investigators are proposing to test individuals at a relatively young age, 18-19 years. This is important to identify a risk factor, that is thought to pre-date use of drugs. In older participants, it would be difficult to separate the role of the pre-existing trait from the effect of habitual drug or alcohol use that escalates markedly after age 20. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03810703
Study type Interventional
Source University of Chicago
Contact
Status Completed
Phase Phase 1
Start date February 9, 2017
Completion date August 9, 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Recruiting NCT05340686 - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression N/A
Completed NCT00761761 - Sensoril(Ashwaganhda)for Bipolar Disorder Phase 3
Active, not recruiting NCT04561622 - Emotional Proactive Processing in Bipolar Disorder
Completed NCT03334721 - Gabapentin for Bipolar & Cannabis Use Disorders Phase 2
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3
Not yet recruiting NCT06184581 - Lithium Versus Lamotrigine in Bipolar Disorder, Type II Phase 4
Active, not recruiting NCT03484494 - Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression N/A
Recruiting NCT05400785 - Efficacy of the Mobile Application for Prediction and Prevention of Mood Episode Recurrence Based on Machine Learning N/A
Completed NCT05340504 - Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder Phase 2
Active, not recruiting NCT05249309 - Naturalistic Study of Ketamine in the Treatment of Depression
Recruiting NCT04211428 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder
Completed NCT03822416 - Treating Smokers With Mental Illness Phase 2
Completed NCT01588457 - Sequential Multiple Assignment Treatment for Bipolar Disorder Phase 4
Completed NCT03156504 - The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. Phase 4
Terminated NCT02491307 - Ginger.io Behavioral Health Study N/A
Recruiting NCT05427123 - Children's Bipolar Network Treatment Trial I
Not yet recruiting NCT05705063 - Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness N/A
Recruiting NCT05065294 - Psilocybin Therapy for Depression in Bipolar II Disorder Phase 2
Completed NCT02593643 - Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression. Early Phase 1